|
DZ2376A1
(fr)
*
|
1996-12-19 |
2002-12-28 |
Smithkline Beecham Plc |
Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
|
|
AU736256B2
(en)
*
|
1997-07-11 |
2001-07-26 |
Smithkline Beecham Plc |
Novel compounds
|
|
CA2318731C
(en)
|
1998-01-29 |
2012-05-29 |
Tularik Inc. |
Ppar-gamma modulators
|
|
GB9803411D0
(en)
*
|
1998-02-18 |
1998-04-15 |
Smithkline Beecham Plc |
Novel compounds
|
|
US6194410B1
(en)
*
|
1998-03-11 |
2001-02-27 |
Hoffman-La Roche Inc. |
Pyrazolopyrimidine and pyrazolines and process for preparation thereof
|
|
GB9810671D0
(en)
*
|
1998-05-18 |
1998-07-15 |
Pfizer Ltd |
Anti-pruritic agents
|
|
GB9818914D0
(en)
*
|
1998-08-28 |
1998-10-21 |
Smithkline Beecham Plc |
Use
|
|
GB9818916D0
(en)
|
1998-08-28 |
1998-10-21 |
Smithkline Beecham Plc |
Use
|
|
GB9820113D0
(en)
|
1998-09-15 |
1998-11-11 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
US7041691B1
(en)
|
1999-06-30 |
2006-05-09 |
Amgen Inc. |
Compounds for the modulation of PPARγ activity
|
|
GB9926302D0
(en)
*
|
1999-11-05 |
2000-01-12 |
Smithkline Beecham Plc |
Novel compounds
|
|
WO2001045694A1
(en)
*
|
1999-12-21 |
2001-06-28 |
Smithkline Beecham Corporation |
Urotensin-ii receptor antagonists
|
|
SE9904723D0
(sv)
*
|
1999-12-22 |
1999-12-22 |
Carlsson A Research Ab |
New modulators of dopamine neurotransmission II
|
|
SE0001899D0
(sv)
|
2000-05-22 |
2000-05-22 |
Pharmacia & Upjohn Ab |
New compounds
|
|
US20030171399A1
(en)
|
2000-06-28 |
2003-09-11 |
Tularik Inc. |
Quinolinyl and benzothiazolyl modulators
|
|
US6818639B2
(en)
|
2000-07-21 |
2004-11-16 |
Biovitrum Ab |
Pharmaceutical combination formulation and method of treatment with the combination
|
|
SE0002754D0
(sv)
*
|
2000-07-21 |
2000-07-21 |
Pharmacia & Upjohn Ab |
New pharmaceutical combination formulation and method of treatment with the combination
|
|
SE0002739D0
(sv)
*
|
2000-07-21 |
2000-07-21 |
Pharmacia & Upjohn Ab |
New use
|
|
US6399617B1
(en)
|
2000-07-21 |
2002-06-04 |
Biovitrum Ab |
Use
|
|
AU2001288053A1
(en)
*
|
2000-09-18 |
2002-03-26 |
Toa Eiyo Ltd. |
N-substituted benzothiophenesulfonamide derivatives
|
|
US7071220B2
(en)
|
2000-09-18 |
2006-07-04 |
Toa Eiyo Ltd. |
N-substituted benzothiophenesulfonamide derivatives
|
|
US7034029B2
(en)
|
2000-11-02 |
2006-04-25 |
Wyeth |
1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
|
|
EP1341783A1
(en)
|
2000-11-21 |
2003-09-10 |
Smithkline Beecham Plc |
Isoquinoline derivatives useful in the treatment of cns disorders
|
|
KR20030064852A
(ko)
|
2000-12-22 |
2003-08-02 |
이시하라 산교 가부시끼가이샤 |
아닐린 유도체 또는 그의 염 및 이들을 함유하는사이토카인 생산 억제제
|
|
WO2002088101A2
(en)
*
|
2001-04-27 |
2002-11-07 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of bace
|
|
EP1385495A4
(en)
*
|
2001-05-07 |
2005-12-21 |
Smithkline Beecham Corp |
SULPHONAMIDES
|
|
JP2004529168A
(ja)
*
|
2001-05-07 |
2004-09-24 |
スミスクライン・ビーチャム・コーポレイション |
スルホンアミド
|
|
US6743796B2
(en)
*
|
2001-05-07 |
2004-06-01 |
Wyeth |
Piperazinyl-isatins
|
|
AR033879A1
(es)
*
|
2001-05-07 |
2004-01-07 |
Smithkline Beecham Corp |
Compuesto sulfonamida, composicion farmaceutica que lo comprende, su uso para preparar dicha composicion y procedimiento para la obtencion de dicho compuesto
|
|
JP2004535390A
(ja)
*
|
2001-05-07 |
2004-11-25 |
スミスクライン・ビーチャム・コーポレイション |
スルホンアミド
|
|
WO2002089793A1
(en)
*
|
2001-05-07 |
2002-11-14 |
Smithkline Beecham Corporation |
Sulfonamides
|
|
GB0111186D0
(en)
*
|
2001-05-08 |
2001-06-27 |
Smithkline Beecham Plc |
Novel compounds
|
|
US7718650B2
(en)
|
2001-05-11 |
2010-05-18 |
Biovitrum Ab |
Aryl sulfonamide compounds for treating obesity
|
|
RS88803A
(sr)
*
|
2001-05-11 |
2007-02-05 |
Biovitrum Ab., |
Nova jedinjenja arilsulfonamida za lečenje gojaznosti, dijabetesa tipa ii i poremećaja cns
|
|
WO2002092585A1
(en)
|
2001-05-11 |
2002-11-21 |
Biovitrum Ab |
Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
|
|
EP1401813B1
(en)
|
2001-06-07 |
2007-02-07 |
F. Hoffman-la Roche AG |
New indole derivatives with 5-ht6 receptor affinity
|
|
IL158590A0
(en)
|
2001-06-11 |
2004-05-12 |
Biovitrum Ab |
Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes
|
|
DE60212841T2
(de)
|
2001-06-15 |
2007-06-21 |
F. Hoffmann-La Roche Ag |
4 piperazinylindolderivate mit affinität zum 5-ht6-rezeptor
|
|
US6727264B1
(en)
*
|
2001-07-05 |
2004-04-27 |
Synaptic Pharmaceutical Corporation |
Substituted anilinic piperidines as MCH selective antagonists
|
|
WO2003013510A1
(en)
*
|
2001-08-07 |
2003-02-20 |
Smithkline Beecham P.L.C. |
3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
|
|
HRP20040090A2
(en)
*
|
2001-08-10 |
2004-12-31 |
Hoffmann La Roche |
Arylsulfonyl derivatives with 5-ht<sub>6</sub> receptor affinity
|
|
JP4221294B2
(ja)
|
2001-09-05 |
2009-02-12 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
摂食亢進剤および食欲不振症治療剤
|
|
SE0103644D0
(sv)
*
|
2001-11-01 |
2001-11-01 |
Astrazeneca Ab |
Therapeutic isoquinoline compounds
|
|
EP1450806B1
(en)
*
|
2001-11-09 |
2009-04-29 |
Biovitrum AB (publ) |
Use of sulfonamide derivatives in the treatment of obesity or for the reduction of food intake
|
|
RS44304A
(sr)
|
2001-11-22 |
2007-06-04 |
Biovitrum Ab., |
Inhibitori 11-beta- hidroksistereoidne dehidrogenaze tipa 1
|
|
RS44204A
(sr)
|
2001-11-22 |
2007-06-04 |
Biovitrum Ab., |
Inhibitori 11-beta- hidroksistereoidne dehidrogenaze tipa 1
|
|
CN1321115C
(zh)
*
|
2001-11-30 |
2007-06-13 |
霍夫曼-拉罗奇有限公司 |
作为哮喘治疗中的ccr－3受体拮抗剂的哌嗪衍生物
|
|
WO2003066056A1
(en)
*
|
2002-02-05 |
2003-08-14 |
Glaxo Group Limited |
Method of promoting neuronal growth
|
|
AU2003203148A1
(en)
*
|
2002-02-05 |
2003-09-02 |
High Point Pharmaceuticals, Llc |
Novel aryl- and heteroarylpiperazines
|
|
KR20040081201A
(ko)
*
|
2002-02-13 |
2004-09-20 |
글락소 그룹 리미티드 |
항정신병제로서 벤젠술폰아미드 유도체
|
|
US20050085461A1
(en)
*
|
2002-02-13 |
2005-04-21 |
Cooper David G. |
Benzenesulfonamide derivatives
|
|
WO2003068751A1
(en)
*
|
2002-02-13 |
2003-08-21 |
Glaxo Group Limited |
7-arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo'diazepine derivatives with 5-ht6 receptor affinity for the reatment of cns disorders
|
|
BRPI0308696B8
(pt)
|
2002-03-27 |
2021-05-25 |
Axovant Sciences Gmbh |
composto derivado de quinolina, seu processo de preparação, sua composição farmacêutica e seus usos
|
|
US20040142948A1
(en)
*
|
2002-05-07 |
2004-07-22 |
Dashyant Dhanak |
Sulfonamides
|
|
HRP20041030B1
(hr)
*
|
2002-05-13 |
2013-03-31 |
F. Hoffmann - La Roche Ag |
Derivati benzoksazina kao regulatori 5-ht6 i njihova upotreba
|
|
EP1513828A1
(en)
*
|
2002-06-20 |
2005-03-16 |
Biovitrum AB |
New compounds useful for the treatment of obesity, type ii diabetes and cns disorders
|
|
JP4754821B2
(ja)
*
|
2002-06-20 |
2011-08-24 |
プロキシマゲン・リミテッド |
肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物
|
|
EP1897881A3
(en)
|
2002-06-20 |
2009-03-18 |
Biovitrum AB (publ) |
Compounds useful for the treatment of obesity, type II diabetes and CNS disorders
|
|
PL376479A1
(en)
|
2002-10-18 |
2005-12-27 |
F.Hoffmann-La Roche Ag |
4-piperazinyl benzenesulfonyl indoles with 5-ht6 receptor affinity
|
|
AU2003295408A1
(en)
*
|
2002-11-06 |
2004-06-03 |
Smithkline Beecham Corporation |
Sulfonamides
|
|
AU2003291262A1
(en)
*
|
2002-11-06 |
2004-06-03 |
Smithkline Beecham Corporation |
Sulfonamides
|
|
MXPA05007485A
(es)
|
2003-01-14 |
2006-01-30 |
Arena Pharm Inc |
Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
|
|
US7153858B2
(en)
|
2003-01-31 |
2006-12-26 |
Epix Delaware, Inc. |
Arylpiperazinyl compounds
|
|
US20060257613A1
(en)
*
|
2003-02-13 |
2006-11-16 |
Horst Berneth |
Metal complexes as light-absorbing compounds in the information layer of optical data carriers
|
|
US7319111B2
(en)
*
|
2003-02-20 |
2008-01-15 |
Encysive Pharmaceuticals, Inc. |
Phenylenediamine Urotensin-II receptor antagonists and CCR-9 antagonists
|
|
TWI289141B
(en)
|
2003-03-11 |
2007-11-01 |
Hoffmann La Roche F. Ag. |
Quinolinone derivatives and uses thereof
|
|
WO2004087654A2
(en)
*
|
2003-03-31 |
2004-10-14 |
Janssen Pharmaceutica N.V. |
Phospholipase c inhibitors for use in treating inflammatory disorders
|
|
US6946466B2
(en)
*
|
2003-04-10 |
2005-09-20 |
Schering Ag |
Aromatic sulfonamides as peroxynitrite-rearrangement catalysts
|
|
US20040204422A1
(en)
*
|
2003-04-14 |
2004-10-14 |
Abbott Gmbh & Co. Kg. |
N-[(Piperazinyl)hetaryl]arylsulfonamide compounds
|
|
PT1558582E
(pt)
|
2003-07-22 |
2006-05-31 |
Arena Pharm Inc |
Derivados de diaril- e aril-heteroaril-ureia como moduladores do receptor de serotonina 5-ht2a uteis para a profilaxia e tratamento de desordens relacionadas com o mesmo
|
|
GB0320320D0
(en)
*
|
2003-08-29 |
2003-10-01 |
Glaxo Group Ltd |
Novel compounds
|
|
US7223761B2
(en)
|
2003-10-03 |
2007-05-29 |
Amgen Inc. |
Salts and polymorphs of a potent antidiabetic compound
|
|
BRPI0417833A
(pt)
*
|
2003-12-19 |
2007-04-17 |
Biovitrum Ab |
novos derivados de benzofurano, os quais podem ser usados na profilaxia ou tratamento de distúrbios relacionados com o receptor 5-ht6
|
|
SE0303480D0
(sv)
|
2003-12-19 |
2003-12-19 |
Biovitrum Ab |
Benzofuranes
|
|
US7381728B2
(en)
*
|
2004-07-28 |
2008-06-03 |
Glaxo Group Limited |
Piperazine derivatives useful for the treatment of gastrointestinal disorders
|
|
CN102114244A
(zh)
*
|
2004-09-30 |
2011-07-06 |
弗·哈夫曼-拉罗切有限公司 |
治疗认知障碍的组合物和方法
|
|
ES2364488T3
(es)
|
2004-10-14 |
2011-09-05 |
ABBOTT GMBH & CO. KG |
Compuestos heterocíclicos adecuados para el tratamiento de trastornos que responden a la modulación del receptor de dopamina.
|
|
ATE520659T1
(de)
|
2004-10-14 |
2011-09-15 |
Abbott Gmbh & Co Kg |
Zur behandlung von auf die modulation des dopamin-d3-rezeptors ansprechenden erkrankungen geeignete azabicycloheptylverbindungen
|
|
WO2006062481A1
(en)
*
|
2004-12-09 |
2006-06-15 |
Biovitrum Ab |
New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
|
|
EP1676841A1
(en)
*
|
2004-12-30 |
2006-07-05 |
Esteve Laboratorios Dr. Esteve S.A. |
Substitited indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds, their prepartion and use in medicaments
|
|
KR100931928B1
(ko)
*
|
2005-01-12 |
2009-12-15 |
인제대학교 산학협력단 |
P25/cdk5 저해 화합물을 포함하는 퇴행성 뇌질환의 예방 및치료용 약학 조성물
|
|
RU2499795C2
(ru)
|
2005-07-04 |
2013-11-27 |
Хай Пойнт Фармасьютикалс, ЛЛС |
Антагонисты гистаминовых н3-рецепторов
|
|
EA013875B1
(ru)
|
2005-08-12 |
2010-08-30 |
Сувен Лайф Сайенсиз Лимитед |
Аминоарильные сульфонамидные производные как функциональные 5-нтлиганды
|
|
WO2007020654A1
(en)
|
2005-08-16 |
2007-02-22 |
Suven Life Sciences |
An improved process for the preparation of losartan
|
|
WO2007076875A2
(en)
*
|
2006-01-06 |
2007-07-12 |
Aarhus Universitet |
Compounds acting on the serotonin transporter
|
|
TW200808709A
(en)
|
2006-03-31 |
2008-02-16 |
Glaxo Group Ltd |
Novel compounds
|
|
TW200808762A
(en)
|
2006-04-19 |
2008-02-16 |
Abbott Gmbh & Co Kg |
Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor
|
|
CA2648891A1
(en)
*
|
2006-04-19 |
2007-10-25 |
Abbott Gmbh & Co. Kg |
Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5ht6 receptor
|
|
US8318927B2
(en)
|
2006-05-23 |
2012-11-27 |
High Point Pharmaceuticals, Llc |
6-(4-cyclopropylpiperazin-1-yl)-2′-methyl-[3, 4′]-bipyridine and its uses as a medicament
|
|
SG163547A1
(en)
|
2006-05-29 |
2010-08-30 |
High Point Pharmaceuticals Llc |
3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
|
|
JP2010508300A
(ja)
*
|
2006-10-26 |
2010-03-18 |
フライン、ギャリー・エー． |
アクアポリン修飾因子並びに浮腫および体液平衡異常の治療のためのそれらの使用方法
|
|
AU2007343063B2
(en)
|
2007-01-08 |
2011-02-17 |
Suven Life Sciences Limited |
5-(Heterocyclyl)alkyl-N-(arylsulfonyl)indole compounds and their use as 5-HT6 ligands
|
|
JP5208963B2
(ja)
*
|
2007-01-10 |
2013-06-12 |
エフ．ホフマン−ラ ロシュ アーゲー |
キマーゼ阻害剤としてのスルホンアミド誘導体
|
|
US8507469B2
(en)
|
2007-03-23 |
2013-08-13 |
Abbott Gmbh & Co. Kg |
Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
|
|
BRPI0809873A2
(pt)
|
2007-05-03 |
2018-11-13 |
Suven Life Sciences Ltd |
"composto, processo para a preparação do composto, método para o tratamento de uma desordem do sistema nervoso central, composição farmacêutica, uso do composto, método para testar antagonistas e antagonistas com seletividade para o receptor 5-th6 e método de tratamento"
|
|
EP2014656A3
(en)
|
2007-06-11 |
2011-08-24 |
High Point Pharmaceuticals, LLC |
New heteocyclic h3 antagonists
|
|
EP2016943B1
(en)
*
|
2007-07-19 |
2011-02-23 |
Laboratorios del Dr. Esteve S.A. |
Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments
|
|
CN101835748B
(zh)
|
2007-10-26 |
2012-11-14 |
苏文生命科学有限公司 |
氨基芳基磺胺化合物及其作为5-ht6配体的用途
|
|
PA8802201A1
(es)
*
|
2007-11-02 |
2009-06-23 |
Abbott Gmbh & Co Kg |
Compuestos de bencensulfonalida apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6
|
|
EP2508177A1
(en)
|
2007-12-12 |
2012-10-10 |
Glaxo Group Limited |
Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
|
|
WO2009123714A2
(en)
|
2008-04-02 |
2009-10-08 |
Arena Pharmaceuticals, Inc. |
Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
|
|
WO2009128058A1
(en)
|
2008-04-18 |
2009-10-22 |
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al |
Psycho-pharmaceuticals
|
|
UA103319C2
(en)
|
2008-05-06 |
2013-10-10 |
Глаксосмитклайн Ллк |
Thiazole- and oxazole-benzene sulfonamide compounds
|
|
EP2297097A2
(en)
*
|
2008-06-11 |
2011-03-23 |
Irm Llc |
Compounds and compositions useful for the treatment of malaria
|
|
WO2010032257A1
(en)
|
2008-09-17 |
2010-03-25 |
Suven Life Sciences Limited |
Aryl indolyl sulfonamide compounds and their use as 5-ht6 ligands
|
|
EP2346847B1
(en)
*
|
2008-09-17 |
2013-05-15 |
Suven Life Sciences Limited |
Aryl sulfonamide amine compounds and their use as 5-ht6 ligands
|
|
WO2010062321A1
(en)
|
2008-10-28 |
2010-06-03 |
Arena Pharmaceuticals, Inc. |
Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
|
|
UA100192C2
(en)
|
2008-11-11 |
2012-11-26 |
УАЙТ ЭлЭлСи |
1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
|
|
KR101073703B1
(ko)
|
2009-04-07 |
2011-10-14 |
한국화학연구원 |
피페라진 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계 질환의 예방 또는 치료용 약학적 조성물
|
|
US8343959B2
(en)
|
2009-04-30 |
2013-01-01 |
Abbott Gmbh & Co. Kg |
N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
|
|
MX2011011519A
(es)
|
2009-04-30 |
2012-01-30 |
Abbott Gmbh & Co Kg |
Compuestos de bencensulfonanilida adecuados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6.
|
|
MX2011011520A
(es)
|
2009-04-30 |
2012-06-19 |
Abbott Gmbh & Co Kg |
Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfon amida o bencensulfonil-fenil-(piperazina u homopiperazina) adecuados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6.
|
|
CN102459199A
(zh)
*
|
2009-04-30 |
2012-05-16 |
雅培股份有限两合公司 |
适于治疗响应于5-羟色胺5-ht6受体调节的病症的苯磺酰苯胺化合物
|
|
CA2786072C
(en)
|
2010-01-05 |
2014-10-28 |
Suven Life Sciences Limited |
Sulfone compounds as 5-ht6 receptor ligands
|
|
PH12013500547A1
(en)
|
2010-09-22 |
2013-06-10 |
Arena Pharm Inc |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
WO2012059431A1
(en)
|
2010-11-01 |
2012-05-10 |
Abbott Gmbh & Co. Kg |
Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
|
|
WO2012059432A1
(en)
|
2010-11-01 |
2012-05-10 |
Abbott Gmbh & Co. Kg |
N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor
|
|
ES2413911B1
(es)
*
|
2011-12-15 |
2014-05-14 |
Universidad De Zaragoza |
Agente inhibidor de la agregación del peptido beta amiloide.
|
|
CA2866910A1
(en)
|
2012-03-20 |
2013-09-26 |
Adamed Sp. Z O.O. |
Sulphonamide derivatives of benzylamine for the treatment of cns diseases
|
|
MX394360B
(es)
|
2013-03-14 |
2025-03-24 |
Sumitomo Pharma Oncology Inc |
Inhibidores de jak2 y alk2 y metodos para su uso.
|
|
DK3027613T3
(en)
|
2013-07-25 |
2018-06-25 |
Univ Jagiellonski |
Pyrroloquinoline derivatives as 5-HT6 antagonists, preparation and use thereof
|
|
WO2015158313A1
(en)
|
2014-04-19 |
2015-10-22 |
Sunshine Lake Pharma Co., Ltd. |
Sulfonamide derivatives and pharmaceutical applications thereof
|
|
CN105367473B
(zh)
*
|
2014-08-12 |
2020-02-11 |
广东东阳光药业有限公司 |
吲哚啉类衍生物及其在药物上的应用
|
|
CN105367472B
(zh)
*
|
2014-08-12 |
2020-04-21 |
广东东阳光药业有限公司 |
吲哚啉类衍生物及其在药物上的应用
|
|
MX386419B
(es)
|
2015-01-06 |
2025-03-18 |
Arena Pharm Inc |
Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
|
|
WO2016201373A1
(en)
|
2015-06-12 |
2016-12-15 |
Axovant Sciences Ltd. |
Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
|
|
EP3939965A1
(en)
|
2015-06-22 |
2022-01-19 |
Arena Pharmaceuticals, Inc. |
Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders
|
|
WO2017011767A2
(en)
|
2015-07-15 |
2017-01-19 |
Axovant Sciences Ltd. |
Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
|
|
CN108926565A
(zh)
*
|
2017-05-26 |
2018-12-04 |
中国科学院上海生命科学研究院 |
五羟色胺受体亚型6小分子激活剂及拮抗剂在防治阿尔茨海默症中的应用
|
|
WO2019180176A1
(en)
|
2018-03-21 |
2019-09-26 |
Spherium Biomed, S.L. |
Composition for the treatment of schizophrenia and/or psychosis
|
|
ES2987794T3
(es)
|
2018-06-06 |
2024-11-18 |
Arena Pharm Inc |
Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
|
|
MX2021000977A
(es)
|
2018-07-26 |
2021-04-12 |
Sumitomo Pharma Oncology Inc |
Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos.
|